Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
editorial
. 2001 May;39(5):2037–2038. doi: 10.1128/JCM.39.5.2037-2038.2001

Discordant Carbapenem Susceptibility in Methylobacterium Species and Its Application as a Method for Phenotypic Identification

G J Zaharatos 1, A Dascal 1, M A Miller 1,*
PMCID: PMC88082  PMID: 11388170

We encountered a meropenem-resistant, imipenem-susceptible clinical Methylobacterium isolate and sought to determine if discordant carbapenem susceptibility (meropenem resistance/imipenem susceptibility) was common among different Methylobacterium species. We concurrently investigated whether this phenotype was expressed in the genus Roseomonas, the other recognized group of pink-pigmented nonfermenting gram-negative bacilli.

The genus Methylobacterium is comprised of pink-pigmented nonfermenting gram-negative bacilli. These organisms are widely distributed in nature and have been isolated from chlorinated potable water supplies (6). Their presence and role as opportunistic pathogens and presence in the nosocomial setting are well documented (1, 4, 5, 7, 9, 10, 14).

Isolates can be cultivated on a variety of solid media, but small colonies may only be detected after incubation for 4 to 5 days (15). Optimal growth occurs at 25 to 30°C; most strains fail to grow at 37°C. Biochemical characterization allows definitive identification and differentiation from other pink-pigmented nonfermenters (15). 16S rRNA-based molecular studies have allowed phylogenetic analysis and rapid identification of Methylobacterium species (6, 13).

Current interpretive standards for antibiotic susceptibility testing do not apply to Methylobacterium species (12). Two large Methylobacterium studies assessing in vitro antibiotic susceptibility have demonstrated broad resistance to beta-lactam antibiotics (2, 6). To date, isolates tested have been imipenem susceptible (1, 7, 9). No data with regard to meropenem susceptibility has been published to our knowledge.

Four clinical isolates from our laboratory were identified as Methylobacterium species, by morphologic and biochemical characteristics, at a reference laboratory (Laboratoire de Santé Publique du Québec). We also acquired three Methylobacterium species and three Roseomonas species from the American Type Culture Collection (ATCC; Table 1).

TABLE 1.

In vitro carbapenem susceptibility of Methylobacterium and Roseomonas spp.a

Isolate Medium Imipenem
Meropenem
Mean zone inhibition (mm) Mean MIC (μg/ml) Mean zone inhibition (mm) Mean MIC (μg/ml)
Methylobacterium spp.
 Isolate no. 1 SDA 44 0.75 6 >32
NA 52 0.25 6 >32
 Isolate no. 2 SDA 48 0.5 6 >32
NA 52 0.25 6 >32
 Isolate no. 3 SDA 48 1 6 >32
NA 50 0.38 6 >32
 Isolate no. 4 SDA 50 0.75 6 >32
NA 48 0.38 6 >32
 Isolate no. 5 (ATCC 29983) SDA 58 0.25 6 >32
NA 64 0.064 6 >32
 Isolate no. 6 (ATCC 43645) SDA 41 0.5 6 >32
NA 52 0.125 6 >32
 Isolate no. 7 (ATCC 27886) SDA 46 0.38 6 >32
NA 50 0.125 6 >32
Roseomonas spp.
Roseomonas genomospecies 5 (ATCC 49960) SDA 63 0.032 68 0.006
NA 64 0.012 69 0.004
R. cervicalis (ATCC 49957) SDA 39 0.75 50 0.023
NA 44 0.094 54 0.012
R. gilardi (ATCC 49956) SDA 55 0.047 47 0.047
NA 58 0.032 54 0.032
a

 Susceptibility was determined by disk diffusion (mean zone inhibition) and E-test (mean MIC) methods on SDA and NA at 25°C for 72 h. Mean MICs from duplicate experiments are rounded up to the nearest E-test scale value. 

Susceptibility testing was performed by E-test (imipenem and meropenem; AB BIODISK) and disk diffusion (imipenem and meropenem, 10-μg disks; OXOID) on Sabouraud dextrose agar (SDA) and nutrient agar (NA). E-test and disk diffusion methods were carried out as described in the manufacturer's instructions and published protocol (11), respectively.

Incubation of plates at 25°C for 72 h allowed all isolates to attain optimal growth for susceptibility determination. All Methylobacterium species isolates were extremely susceptible to imipenem but highly resistant to meropenem (Table 1). All Roseomonas isolates were extremely susceptible to both carbapenems.

In vitro, meropenem is more active than imipenem against members of the family Enterobacteriaceae and most oxidase-positive and/or glucose-nonfermenting gram-negative bacilli (3, 8). The marked discordance between meropenem and imipenem susceptibility that we describe has not to our knowledge been observed in other gram-negative bacilli.

We assessed three distinct Methylobacterium reference strains. 16S rRNA-based phylogenetic analysis has previously placed these species within two major subclusters (subcluster I, M. extorquens and M. organophilum; subcluster II, M. mesophilicum) (6). Given the interspecies consistency of the susceptibility phenotype we describe, it seems plausible that the mechanisms contributing to this phenotype are conserved at the genus level. Further in vitro study is needed to characterize the underlying mechanism for this discordant susceptibility.

Our findings could contribute to more rapid identification of clinical Methylobacterium isolates and conceivably could be exploited for screening potable water supplies and environmental samples. Additionally, our data suggests that discordant carbapenem susceptibility may have the potential to differentiate between Methylobacterium and Roseomonas species. However, our observations include a small number of isolates. Further studies are necessary to confirm our findings and to elucidate the responsible mechanism.

REFERENCES

  • 1.Brown M A, Greene J N, Sandin R L, Hiemenz J W, Sinnott J T. Methylobacterium bacteremia after infusion of contaminated autologous bone marrow. Clin Infect Dis. 1996;23:1191–1192. doi: 10.1093/clinids/23.5.1191. [DOI] [PubMed] [Google Scholar]
  • 2.Brown W J, Sautter R L, Crist A E., Jr Susceptibility testing of clinical isolates of Methylobacterium species. Antimicrob Agents Chemother. 1992;36:1635–1638. doi: 10.1128/aac.36.8.1635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Edwards J R, Turner P J. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis Suppl. 1995;96:5–10. [PubMed] [Google Scholar]
  • 4.Fernandez M, Dreyer Z, Hockenberry-Eaton M, Baker C J. Methylobacterium mesophilica as a cause of persistent bacteremia in a child with lymphoma. Pediatr Infect Dis J. 1997;16:1007–1008. doi: 10.1097/00006454-199710000-00023. [DOI] [PubMed] [Google Scholar]
  • 5.Flournoy D J, Petrone R L, Voth D W. A pseudo-outbreak of Methylobacterium mesophilica isolated from patients undergoing bronchoscopy. Eur J Clin Microbiol Infect Dis. 1992;11:240–243. doi: 10.1007/BF02098087. [DOI] [PubMed] [Google Scholar]
  • 6.Hiraishi A, Furuhata K, Matsumoto A, Koike K A, Fukuyama M, Tabuchi K. Phenotypic and genetic diversity of chlorine-resistant Methylobacterium strains isolated from various environments. Appl Environ Microbiol. 1995;61:2099–2107. doi: 10.1128/aem.61.6.2099-2107.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hornei B, Lüneberg E, Schmidt-Rotte H, Maab M, Weber K, Heits F, Frosch M, Solbach W. Systemic infection of an immunocompromised patient with Methylobacterium zatmanii. J Clin Microbiol. 1999;37:248–250. doi: 10.1128/jcm.37.1.248-250.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jorgesen J H, Maher L A, Howell A W. Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrob Agents Chemother. 1991;35:2410–2414. doi: 10.1128/aac.35.11.2410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kaye K M, Macone A, Kazanjian P H. Catheter infection caused by Methylobacterium in immunocompromised hosts: report of three cases and review of the literature. Clin Infect Dis. 1992;14:1010–1014. doi: 10.1093/clinids/14.5.1010. [DOI] [PubMed] [Google Scholar]
  • 10.Liu J W, Wu J J, Chen H M, Huang A H, Ko W C, Chuang Y C. Methylobacterium mesophilicum synovitis in an alcoholic. Clin Infect Dis. 1997;24:1008–1009. doi: 10.1093/clinids/24.5.1008. [DOI] [PubMed] [Google Scholar]
  • 11.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2–A7. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000. [Google Scholar]
  • 12.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplement M100–S10. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000. [Google Scholar]
  • 13.Nishio T, Yoshikura T, Itoh H. Detection of Methylobacterium species by 16S rRNA gene-targeted PCR. Appl Environ Microbiol. 1997;63:1594–1597. doi: 10.1128/aem.63.4.1594-1597.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sanders J W, Martin J W, Hooke M, Hooke J. Methylobacterium mesophilicum infection: case report and literature review of an unusual opportunistic pathogen. Clin Infect Dis. 2000;30:936–938. doi: 10.1086/313815. [DOI] [PubMed] [Google Scholar]
  • 15.Schreckenberger P C, von Graevenitz A. Acinetobacter, Achromobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative gram-negative rods. In: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, editors. Manual of clinical microbiology. 7th ed. Washington, D.C.: American Society for Microbiology; 1999. pp. 551–552. [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES